Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report
DOI: https://doi.org/10.2147/jhc.s464519
2024-06-05
Journal of Hepatocellular Carcinoma
Abstract:Xianmin Zhu, 1 Shuang Dong, 1 Jing Tang, 1 Rong Xie, 1 Huijing Wu, 1 Jun Guan, 2 Sheng Hu 1 1 Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 2 Department of Hematology, Wuhan NO.1 Hospital, Wuhan, People's Republic of China Correspondence: Sheng Hu, Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, 116 South Road, Wuhan, 430079, People's Republic of China, Email In recent years, there have been limited reports on the efficacy of later-line anti-programmed cell death − 1 (PD-1) therapy in achieving prolonged and complete remission in patients with hepatocellular carcinoma (HCC). Tislelizumab, a humanized anti-PD-1 monoclonal IgG4 antibody, has shown promising results in the treatment of HCC. This report highlights the case of a patient with HCC who experienced the development of lung metastatic lesions following HCC resection and chemotherapy, but achieved a prolonged complete response (CR) after receiving tislelizumab treatment. In April 2017, a 56-year-old male diagnosed with primary HCC underwent hepatectomy and hepatic arterial infusion pump placement. Following the surgery, the patient received adjuvant hepatic arterial infusion chemotherapy (HAIC) with 4 cycles of cisplatin+5-fluorouracil (PF) regimen starting in June 2017. In May 2018, lung metastatic lesions were detected, and the patient underwent 4 cycles of oxaliplatin+leucovorin+5-fluorouracil (FOLFOX) chemotherapy. However, the disease progressed in August 2018, leading to the administration of arsenic trioxide treatment. Despite this, further progression was observed in October 2018, prompting the patient's enrollment in a clinical trial for tislelizumab therapy. Initially, the patient achieved a partial response (PR) to tislelizumab, which was followed by a CR that lasted for almost 4 years. Unfortunately, tislelizumab treatment had to be discontinued due to immune-related adverse events (AE). Subsequently, the patient received lenvatinib and maintained a CR until July 2023. Tislelizumab monotherapy, when used as a third-line treatment, has demonstrated remarkable efficacy in facilitating patients with advanced HCC to attain a durable CR. Keywords: hepatocellular carcinoma, complete response, immune checkpoint inhibitor, tislelizumab, chemotherapy failure, metastasis Hepatocellular carcinoma (HCC) is a highly aggressive and life-threatening liver cancer. 1,2 Globally, the age-standardized annual mortality rate of HCC is 12.9 per 100,000 in men and 4.8 per 100,000 in women. 3 In China, the incidence of HCC is particularly high due to the prevalence of hepatitis B and C infections, with age-adjusted incidence rates of 26.7 per 100,000 men and 8.9 per 100,000 women. 4 Surgical resection, the primary treatment option for HCC, is only feasible for approximately 50% of patients at the time of initial diagnosis. Even after resection, the rates of recurrence and metastasis remain high. 1,2,5 The recurrence rate after curative resection or ablation is reported to exceed 70% within 5 years, even in patients who are considered highly likely to be cured. 6 The risk of HCC recurrence exhibits a bimodal distribution, with the highest recurrence rate occurring within 1–2 years after resection or ablation. 7–9 Early recurrence is often attributed to occult micro-metastasis of the primary tumor, driven by the invasive characteristics of the primary tumor (including tumor size, multiplicity, vascular invasion, high histological grade, and elevated serum alpha-fetoprotein [AFP] levels, etc.), and early recurrence of HCC is commonly considered to be more invasive and associated with poorer long-term clinical outcomes. 9–11 In recent years, significant advancements in systemic therapies for recurrent or metastatic advanced HCC have emerged. According to the latest National Comprehensive Cancer Network (NCCN) guidelines, first-line treatments now include the combination of atezolizumab and bevacizumab, or tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib. 12 Furthermore, major research efforts have been done in the postoperative setting for patients with curative intent. The IMbrave050 study showed that, in patients with high-risk surgically resected or ablated HCC, adjuvant atezolizumab plus bevacizumab was associated with significantly improved recurrence-free survival, which was considered as a standard of care. 13,14 However, the optimal second-line treatment for advanced liver cancer is unclear, especially for patients who have progressed on first-line treatments targetin -Abstract Truncated-
oncology